NEW

Getinge, Cook Medical Reach iCast Distribution Agreement

Getinge and Cook Medical have announced an exclusive sales and distribution agreement for the iCast covered stent system.

Endorail Earns FDA 510(k) clearance: Next-generation magnetic balloon technology optimizes colonoscopy procedural outcomes

Endostart, a pioneering medical device company specializing in gastrointestinal endoscopy solutions, HAS announces a major breakthrough with the FDA 510(k) clearance of its flagship product, Endorail. This achievement represents a significant step forward in advancing...

Survey: Nurse Shortage a Leading Threat to Industry

In honor of Certified Nurses Day, health tech company Carta Healthcare®, whose mission is to harness the value of clinical data, today released the results of a survey about the pain points that health care professionals are currently experiencing. The survey also...

Modular Lab Furniture Systems Meet Needs

UniLine Furniture offerings from HEMCO Corp. include base cabinets, wall cabinets, countertops, sinks, fixtures, base tables, mobile work stations, specialty storage cabinets and peg boards.

Getinge Announces Medical Device Recall

Getinge has announced a global medical device recall related to specific Sevoflurane vaporizers for Flow Family Anesthesia systems. To date, no patient or operator adverse events have been reported. Getinge has reported to relevant authorities according to applicable regulations and is now informing affected customers about the issue through a field safety notice/recall. The cost for the field action is not material.

The vaporizer is the unit containing anaesthetic agent and is available for the anaesthetic agents Sevoflurane, Desflurane and Isoflurane. This issue is only applicable for specific Vaporizers used for certain types of Sevoflurane, which is used as an inhalational anesthetic for induction and maintenance of general anesthesia.

Getinge has received eight complaints describing the presence of a yellow substance in the vaporizer. This issue has only been observed when using certain types of Sevoflurane. No patient or operator adverse events have been reported in any of these complaints.

Getinge will continue to investigate and will provide an update once the root cause and/or corrective actions are identified. Customers are requested to follow the instructions in the field safety notice/ field correction notice until further communication from Getinge.

This information is released in order to inform users of mentioned Getinge products, according to standard procedure recommended by regulatory authorities.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X